Gene x Environment Interplay in Developmental Dyslexia Treatment: A Round-trip Translation Between Humans and Animal

Status: Recruiting
Location: See location...
Intervention Type: Behavioral
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

Developmental dyslexia affects 7% of school-age children (Male:Female ratio of 1.5:1) and incurs disadvantages in education and occupation. Scientific progress concerning the etiology of developmental dyslexia evidenced the complex gene-environment interaction. The DCDC2-READ1 deletion associates with reading skills and affects the magnocellular-dorsal stream in humans and animals. DCDC2 modifies neural activity within the excitatory pathways. The magnocellular-dorsal stream mediates the function of the attention network. Difficulties in spatial and temporal attention shifting impair letter-to-speech sound integration increasing neural noise. Action video games improve the efficiency of the magnocellular-dorsal stream. The aim of this cutting-edge, round trip translation study is threefold: 1.to unravel new insights behind the pathophysiology of developmental dyslexia, 2. to assess gene-environment interaction effects on developmental dyslexia endophenotypes, and 3. to identify useful clues to foster the identification of new, personalized treatments.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 5
Maximum Age: 6
Healthy Volunteers: t
View:

• 5-years old pre-readers,

• normal intelligence quotient,

• no main counter indications for magnetic resonance acquisition,

• no previous diagnosis of any neurodevelopmental disorders.

Locations
Other Locations
Italy
Scientific Institute IRCCS E Medea
RECRUITING
Bosisio Parini
Contact Information
Primary
Sara Mascheretti
sara.mascheretti@lanostrafamiglia.it
031877895
Time Frame
Start Date: 2023-04-30
Estimated Completion Date: 2026-04-30
Participants
Target number of participants: 60
Treatments
Experimental: ENVIRONMENTAL STIMULATION
Related Therapeutic Areas
Sponsors
Collaborators: Università degli studi di Bergamo
Leads: IRCCS Eugenio Medea

This content was sourced from clinicaltrials.gov